Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present at Investor Conferences in June

BOSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron...
May 23, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting

BOSTON, May 23, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
May 09, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports First Quarter 2019 Financial Results

Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as plannedInitiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announcedOdevixibat pivotal trial in biliary atresia...
May 02, 2019 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast

BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
April 13, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019

- Reduction in serum bile acids and pruritus observed in both populations – - Alagille abstract selected for inclusion in ’Best of ILC’ – - Albireo plans to initiate second A4250 pivotal program in...
April 11, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

– Initiation of Phase 2 clinical trial expected in Q2 2019 – – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:...
April 01, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo to Present at Investor Conferences in April

BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced...
March 27, 2019 08:48 ET | Source: Albireo Pharma, Inc.

Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019

BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that...
March 21, 2019 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer

-- Significant recent rare disease product launch and access experience -- -- Key addition as Albireo prepares for commercialization of A4250 -- BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- Albireo...
March 07, 2019 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Year-End 2018 Financial Results and Provides Pipeline Update

- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout -- Plan to initiate second A4250 pivotal program in biliary atresia -- Plan to initiate Phase 2 study with...